A: It is generally recommended to follow your doctor's instructions regarding timing
In terms of safety, tesofensine was well tolerated with a low incidence of adverse events similar to the placebo group
Drug-specific variables that may affect half-life Drug formulation (ie, modified or controlled release preparations extend half-life) How the drug behaves in the body (ie, zero-order, first-order, or multi-compartmental pharmacokinetics) How the drug is administered (half-life may be different with IV administration, compared to intranasal or oral administration) How the drug is cleared from the body (eg, kidneys, liver, lungs) If the drug accumulates in fat or other types of tissue If the drug binds to proteins or not Presence of metabolites or other drugs that may interact Properties of the drug, including molecule size, charge, and pKa The volume of distribution of a drug Other variables, such as if the drug is actively transported, is self-induced, or has saturation pharmacokinetics
Matar (Camperdown, Australia) Objective: Sleep disturbances are prevalent in dementia with Lewy bodies (DLB) however few studies have measured objective sleep in this population
IFAT results also demonstrated this possible release, as manifested by the apparent shift of GSTs from the acinus toward the salivary ducts during blood-feeding
